JAZZ

Jazz PublicA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

28%

Probability

Target price

$255.00

+12.8% vs current

Most likely

Base case

47%

Probability

Target price

$228.00

+0.8% vs current

B-

Bear case

25%

Probability

Target price

$195.00

-13.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Tone is cautiously constructive after the May 5, 2026 earnings release. Company-source evidence confirms 19% YoY revenue growth, non-GAAP adjusted EPS of $6.34, reaffirmed 2026 guidance, and a clear August 25, 2026 PDUFA date for zanidatamab in 1L HER2+ GEA. Secondary coverage reported the print as an EPS and revenue beat and described a positive immediate stock reaction, with the May 7 anchor price of $226.96 above pre-print references cited in market coverage. Analyst-revision evidence is present but still thin in the packet, so missing breadth of target and estimate changes should keep the memo tentative rather than bullish.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-05-20catalystPost-earnings revision and digestion cycleMedium impact

Jazz reported Q1 2026 total revenue of $1.0689 billion versus $897.8 million a year earlier, GAAP EPS of $4.43, non-GAAP adjusted EPS of $6.34, and reaffirmed 2026 revenue and expense guidance; secondary coverage described the print as ahead of consensus and noted at least some positive analyst follow-through, but broad estimate and target-revision evidence remains incomplete [#PR-2026-05-05] [#10-Q-2026-05-05].

2026-08-25eventZanidatamab 1L HER2+ GEA FDA decisionHigh impact

Jazz's May 5, 2026 company release said the FDA accepted the zanidatamab sBLA in first-line HER2-positive gastroesophageal adenocarcinoma for Priority Review, with a PDUFA date of August 25, 2026; this remains the cleanest dated regulatory catalyst, but it is still binary and should not be treated as de-risked approval [#PR-2026-05-05] [#8-K-2026-05-05].

2026-12-31catalystCommercial execution and oncology pipeline readoutsHigh impact

The company attributed 19% YoY revenue growth to higher Xywav, Zepzelca, Epidiolex/Epidyolex sales and Modeyso contribution, while flagging a mid-2026 second interim OS analysis for HERIZON-GEA-01 and a late-2026 to early-2027 top-line readout for the Phase 3 ACTION trial of Modeyso; these are meaningful follow-through markers, but execution must continue across launches and trials [#PR-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology